Pharmicell Co (A005690) Q2 2024 earnings summary

Executive summary

• Operates two main divisions: Bio-Medical (stem cell therapies, storage, cosmetics) and Bio-Chemical (pharmaceutical intermediates, flame retardants, specialty chemicals).

• No subsidiaries or affiliates as of the reporting date; company listed since 1988.

• Recent milestones include new plant completions and leadership changes in 2024.

Financial highlights

• 2024 H1 revenue: ₩28,784M, down from ₩56,227M in 2023 H1.

• Operating income: ₩229M (2024 H1), down from ₩1,296M (2023 H1).

• Net income: ₩1,463M (2024 H1), down from ₩3,578M (2023 H1).

• Cash and equivalents: ₩5,032M at June 2024, down from ₩13,724M at Dec 2023.

• Total assets: ₩90,309M; equity: ₩81,850M; liabilities: ₩8,459M as of June 2024.

Outlook and guidance

• Ongoing clinical trials for stem cell therapies in liver cirrhosis, erectile dysfunction, and chronic kidney disease.

• Continued investment in R&D, with 13% of H1 2024 sales spent on research.

• Expansion of production capacity for nucleosides and mPEG to meet growing demand.